Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLZ-100 in Soft Tissue Sarcoma Surgery
NCT02464332Phase 1Withdrawn
- Sponsor
- Blaze Bioscience
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tozuleristide in soft tissue sarcoma (STS), sponsored by Blaze Bioscience. Primary endpoint: Number of participants with adverse events at 7 days. Planned start Sep 2015; status: withdrawn.
02
Drugs
tozuleristide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02464332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464332.